摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(+)-(4aS,8aS,10aR)-8a-(hydroxymethyl)-1,1,4a-trimethyl-3,4,4a,6,7,8,8a,9,10,10a-decahydrophenanthren-2(1H)-one | 936475-64-8

中文名称
——
中文别名
——
英文名称
(+)-(4aS,8aS,10aR)-8a-(hydroxymethyl)-1,1,4a-trimethyl-3,4,4a,6,7,8,8a,9,10,10a-decahydrophenanthren-2(1H)-one
英文别名
(4aS,8aS,10aR)-8a-(hydroxymethyl)-1,1,4a-trimethyl-3,4,6,7,8,9,10,10a-octahydrophenanthren-2-one
(+)-(4aS,8aS,10aR)-8a-(hydroxymethyl)-1,1,4a-trimethyl-3,4,4a,6,7,8,8a,9,10,10a-decahydrophenanthren-2(1H)-one化学式
CAS
936475-64-8
化学式
C18H28O2
mdl
——
分子量
276.419
InChiKey
UZXHDDWWXSUKEZ-DOPJRALCSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    20
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.83
  • 拓扑面积:
    37.3
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Novel Tricyclic Compounds Having Acetylene Groups at C-8a and Cyano Enones in Rings A and C:  Highly Potent Anti-inflammatory and Cytoprotective Agents
    作者:Tadashi Honda、Chitra Sundararajan、Hidenori Yoshizawa、Xiaobo Su、Yukiko Honda、Karen T. Liby、Michael B. Sporn、Gordon W. Gribble
    DOI:10.1021/jm070141c
    日期:2007.4.1
    Novel C-8a functionalized tricyclic compounds having cyano enones in rings A and C have been synthesized and biologically evaluated. Among them, compounds with acetylene groups at C-8a show extremely high potency in in vitro and in vivo bioassays for anti-inflammatory and cytoprotective activities. Both in vitro and in vivo potencies are markedly higher than those of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic
    已经合成并在生物学上评估了在环A和C中具有氰基烯酮的新型C-8a官能化三环化合物。其中,在C-8a处具有乙炔基的化合物在体外和体内生物测定中显示出极高的抗炎和细胞保护活性。体外和体内效能均显着高于2-氰基3,12-二氧代油菜-1,9(11)-二烯-28-酸(CDDO),后者正被评估为抗癌药物我进行临床试验。
  • Tricyclic-bis-enone derivatives and methods of use thereof
    申请人:——
    公开号:US20030232786A1
    公开(公告)日:2003-12-18
    Novel tricyclic-bis-enone derivatives (TBEs) as well as the process for the preparation of such TBEs are provided. Also provided are methods for prevention and/or treatment of cancer, Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotropic lateral sclerosis, rheumatoid arthritis, inflammatory bowel disease, and all other diseases whose pathogenesis is believed to involve excessive production of either nitric oxide (NO) or prostaglandins or the overexpression of iNOS or COX-2 genes or gene products. Further, methods for the synthesis of the TBE compounds of the invention utilize cheap commercially available reagents and are highly cost effective and amenable to scale-up. Additional high efficiency synthetic methods that utilize novel intermediates as well as the synthesis of these intermediates are also provided. Furthermore, the invention also provides methods for designing novel and water-soluble TBEs.
    提供了新型三环双烯酮衍生物(TBEs)以及制备此类TBEs的方法。还提供了用于预防和/或治疗癌症、阿尔茨海默病、帕金森病、多发性硬化症、肌萎缩侧索硬化、类风湿性关节炎、炎症性肠病以及所有其他疾病的方法,这些疾病的发病机制被认为涉及过量产生一氧化氮(NO)或前列腺素或iNOS或COX-2基因或基因产物的过度表达。此外,本发明的TBE化合物的合成方法利用廉价的商业可获得试剂,具有高成本效益且易于扩展。还提供了利用新型中间体的高效合成方法以及这些中间体的合成。此外,本发明还提供了设计新型水溶性TBEs的方法。
  • [EN] A NOVEL METHOD FOR SYNTHESIZING TBE-31<br/>[FR] NOUVEAU PROCÉDÉ DE SYNTHÈSE DU TBE-31
    申请人:UNIV NEW YORK STATE RES FOUND
    公开号:WO2014151181A1
    公开(公告)日:2014-09-25
    A process for the synthesis of (±)-(4bS,8aR,10aS)-10a-ethynyl-4b,8,8-trimethyl-3,7-dioxo-3,4b,7,8,8a,9,10,10a-octahydrophenanthrene-2,6-dicarbonitrile ("TBE-31"), which is useful for the treatment of various diseases and disorder in mammals. (±)-8a-(Hydroxymethyl)-1,4a-dimethyl-2,3,4,4a,6,7,8,8a,9,10-decahydrophenanthren-2-ol; (±)-8a-(Hydroxymethyl)-1,4a-dimethyl-4,4a,6,7,8,8a,9,10-octahydrophenanthren-2(3H)-one; (±)-(2R,4aS,8aS)-8a-(Hydroxymethyl)-1,4a-dimethyl-2,3,4,4a,6,7,8,8a,9,10-decahydrophenanthren-2-ol; (±)-(2S,4aS,8aS)-8a-(Hydroxymethyl)-1,4a-dimethyl-2,3,4,4a,6,7,8,8a,9,10-decahydrophenanthren-2-ol; and (±)-(4aS,8aS)-8a-(Hydroxymethyl)-1,4a-dimethyl-4,4a,6,7,8,8a,9,10-octahydrophenanthren-2(3H)-one (4).
    一种合成(±)-(4bS,8aR,10aS)-10a-乙炔基-4b,8,8-三甲基-3,7-二酮-3,4b,7,8,8a,9,10,10a-辛氢苯并-2,6-二腈(“TBE-31”)的方法,该方法对哺乳动物的各种疾病和紊乱具有治疗作用。 (±)-8a-(羟甲基)-1,4a-二甲基-2,3,4,4a,6,7,8,8a,9,10-十氢苯并-2-醇;(±)-8a-(羟甲基)-1,4a-二甲基-4,4a,6,7,8,8a,9,10-辛氢苯并-2(3H)-酮;(±)-(2R,4aS,8aS)-8a-(羟甲基)-1,4a-二甲基-2,3,4,4a,6,7,8,8a,9,10-十氢苯并-2-醇;(±)-(2S,4aS,8aS)-8a-(羟甲基)-1,4a-二甲基-2,3,4,4a,6,7,8,8a,9,10-十氢苯并-2-醇;以及(±)-(4aS,8aS)-8a-(羟甲基)-1,4a-二甲基-4,4a,6,7,8,8a,9,10-辛氢苯并-2(3H)-酮(4)。
  • SYNTHESIS AND BIOLOGICAL ACTIVITIES OF NEW TRICYCLIC-BIS-ENONES (TBES)
    申请人:Honda Tadashi
    公开号:US20080261985A1
    公开(公告)日:2008-10-23
    This invention describes novel tricyclic-bis-enone derivatives (TBEs), such as TBE-31, TBE-34, TBE-45 and water-soluble TBEs. The methods of preparing these compounds are also disclosed. The inventors demonstrate the ability of these new TBEs to inhibit proliferation of human myeloma cells, inhibit the induction of iNOS in cells stimulated with interferon-γ, induce heme oxygenase-1 (HO-1), induce CD11b expression—a leukemia differentiation marker, inhibit proliferation of leukemia cells, induce apoptosis in human lung cancer, and induce apoptosis in other cancerous cells. The TBEs of this invention are expected to be useful agents for the treatment and prevention of many diseases, including cancer, neurological disorders, inflammation, and pathologies involving oxidative stress.
    这项发明描述了新的三环双烯酮衍生物(TBEs),如TBE-31、TBE-34、TBE-45和水溶性TBEs。还公开了制备这些化合物的方法。发明人展示了这些新TBEs抑制人骨髓瘤细胞增殖的能力,抑制干扰素-γ刺激下细胞中iNOS的诱导,诱导血红素氧合酶-1(HO-1),诱导CD11b表达-一种白血病分化标志物,抑制白血病细胞增殖,诱导人肺癌细胞凋亡,并诱导其他癌细胞凋亡。这项发明的TBEs预计将成为治疗和预防许多疾病的有用药物,包括癌症、神经系统疾病、炎症和涉及氧化应激的病理学。
  • MONOCYCLIC CYANOENONES AND METHODS OF USE THEREOF
    申请人:Honda Tadashi
    公开号:US20110196007A1
    公开(公告)日:2011-08-11
    The present invention features monocyclic cyanoenone compositions and methods for using the same in the treatment of diseases such as cancer, inflammatory diseases and neurodegenerative diseases.
    本发明涉及单环氰基烯酮组合物及其在治疗癌症、炎症性疾病和神经退行性疾病等疾病中的应用方法。
查看更多